Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-19 DNA Vaccine Candidate, INO-4800

08/26/2021 | 08:00am EDT

INOVIO announced that it has received regulatory authorization from Brazil'sANVISA (Agência Nacional de Vigilância Sanitária), the national health regulatory agency of Brazil, to initiate the global Phase 3 segment of its Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), for INO-4800, its DNA vaccine candidate for COVID-19. INOVIO plans to conduct the global INNOVATE Phase 3 segment in multiple countries, including Brazil, with partner Advaccine Biopharmaceuticals Suzhou Co. Ltd. (Advaccine). The global Phase 3 segment of the INNOVATE Phase 2/3 clinical trial will evaluate the efficacy of INO-4800 in a two-dose regimen (2.0 mg per dose), administered one month apart, in a two-to-one randomization in men and non-pregnant women 18 years of age and older in several countries across Latin America, Asia, and Africa. The primary endpoint of this case-driven Phase 3 trial is virologically confirmed COVID-19. INOVIO's DNA medicines have shown the following overall characteristics: Well-tolerated and Easy to Administer: INO-4800 has a strong safety profile and, unlike other COVID-19 vaccine candidates, INO-4800 is administered intradermally and has caused only very limited side effects (mostly mild injection site reactions). Immunogenic: INO-4800 demonstrated robust immune responses: 100% of Phase 1 participants demonstrated overall immunological response rates and had balanced neutralizing antibodies and favorable T-cell responses (CD8 and CD4). Stable and Transportable: INO-4800 has a favorable thermostability profile. The vaccine candidate is projected to be stable at room temperature for more than a year, at 37°C for more than a month, has a 3 to 5-year projected shelf life at 2-8°C and does not need to be frozen during transport or storage – a critical element when considering the feasibility of global distribution. Characterizable and Scalable: INO-4800 is highly characterizable, scalable to population levels, and safe. The highly characterizable nature of the vaccine enables timely scaling of manufacturing with multiple manufacturing facilities able to be utilized. Repeat Administration: INO-4800 can be safely readministered offering the potential for seasonal boosting usage without any concerns of generating an anti-vector response or formulation related issues. The global Phase 3 segment of the Phase 2/3 INNOVATE trial builds upon the Phase 2 segment conducted in the U.S., which was funded by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency. Results from the trial can be found in the paper entitled "Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A Preliminary Report of a Randomized, Blinded, Placebo-controlled, Phase 2 Clinical Trial in Adults at High Risk of Viral Exposure," which has been disclosed in a pre-print in MedRxiv prior to peer review. Early INO-4800 research and development funding were provided by the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation. The Phase 2 data showed INO-4800 was well-tolerated and immunogenic in adults 18 and older. In another previously disclosed study using clinical samples, INO-4800 was also found to provide broad cross-reactive immune responses, including neutralizing antibodies and robust T cell responses, against variants of concern (alpha, beta, gamma and – in subsequent research – delta) – factors which could be critical in containing the SARS-CoV-2 virus as it shifts from pandemic to endemic spread. Earlier this month, INOVIO announced the authorization to proceed in China with two clinical trials investigating heterologous boosting with INO-4800 through Advaccine as the trial sponsor. Working with Sinovac Biotechnology (Sinovac), Advaccine will evaluate the safety, tolerability, and immunogenicity of heterologous prime-boost sequential immunizations using INO-4800 and CoronaVac®, an inactivated COVID-19 vaccine developed by Sinovac and authorized for emergency use by the World Health Organization.

© S&P Capital IQ 2021
10/12INOVIO PHARMACEUTICALS : Announces Online Preprint Publication of Homologous Boosting Data..
10/12Inovio Pharmaceuticals, Inc. Announces Online Preprint Publication of Homologous Boosti..
10/11INOVIO PHARMACEUTICALS : Secures Approval to Conduct Phase 3 Trial of COVID-19 DNA Vaccine..
10/11INOVIO PHARMACEUTICALS : Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate ..
10/11INOVIO Expands Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include..
09/29INOVIO PHARMACEUTICALS : to Present Three Posters at IDWeek 2021
09/22INOVIO PHARMACEUTICALS : Gets Approval from Mexico Regulator for COVID-19 Vaccine Efficacy..
09/22INOVIO PHARMACEUTICALS : Receives Regulatory Authorization to Conduct Phase 3 Efficacy Tri..
09/22INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID..
09/10INOVIO PHARMACEUTICALS : BofA Securities Downgrades Inovio Pharmaceuticals to Underperform..
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 4,71 M - -
Net income 2021 -272 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,40x
Yield 2021 -
Capitalization 1 477 M 1 477 M -
Capi. / Sales 2021 314x
Capi. / Sales 2022 15,0x
Nbr of Employees 262
Free-Float 98,3%
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 7,02 $
Average target price 13,22 $
Spread / Average Target 88,4%
EPS Revisions
Managers and Directors
J. Joseph Kim President, Chief Executive Officer & Director
Peter D. Kies Chief Financial Officer
Simon X. Benito Chairman
Laurent M. Humeau Chief Scientific Officer
Kate E. Broderick Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.220.51%135 157
LONZA GROUP AG27.29%58 232
SEAGEN INC.-1.81%31 287
CELLTRION, INC.-39.69%24 952